NFKB1 and Parkinson disease: Dexmedetomidine has the capacity to reduce the dorsal horn of the spinal cord astrocyte activation and inflammation by activating AMPK and blocking the mammalian target of the rapamycin (mTOR)/NF-κB pathway, therefore protecting DA neurons in PD [205].